Quanterix reported Q2 2026 revenue of $32.9 million, a 34% increase year-over-year, but recorded a net loss of $48.9 million and incurred a $26.9 million goodwill impairment related to its Akoya acquisition. The company revised its full-year 2026 revenue guidance downward to $142–$148 million from the previous range of $169–$174 million, citing execution challenges and market softness. Consequently, Quanterix extended its cash flow breakeven timeline to 2027 and lowered its year-end cash balance forecast to approximately $80 million. Additionally, the firm appointed Jim Gute as Chief Commercial Officer to lead commercial re-acceleration efforts.

Quanterix Corporation has appointed Jason Faessler as Chief Financial Officer and Treasurer, effective June 22, 2026. Mr. Faessler, formerly of Brucker Corporation and Parexel Corporation, will receive an annualized base salary of $475,000, a $200,000 sign-on bonus, and an annual performance bonus target of up to 50% of his base salary. He will also receive a long-term equity incentive award of restricted stock units (RSUs) equivalent to 0.30% of the company's outstanding common stock. Quanterix Corporation is a biotechnology company that develops and manufactures high-sensitivity protein detection technology.